Pathogen-Associated Malignancies Integrated Research Center
Leadership & Faculty
The Pathogen-Associated Malignancies Integrated Research Center (PAM IRC) brings together investigators with basic, translational, public health and clinical expertise who are committed to translation of basic findings from the laboratory to the clinic.
PAM IRC Leadership
Dr. Denise Galloway, PhD
Dr. Denise Galloway oversees the PAM IRC’s vision and direction. She studies two cancer-causing viruses: The human papillomavirus, linked to all cervical cancers and a growing number of oropharyngeal and head and neck cancers, and Merkel cell polyomavirus, which causes 80 percent of Merkel cell carcinoma, a rare but aggressive skin cancer. Her work helped pave the way for the cancer-preventive HPV vaccine and led to a simple blood test to detect MCC recurrence.
Dr. Nina Salama, PhD
Dr. Nina Salama works closely with Dr. Galloway to direct the PAM IRC. She leads mentoring and outreach efforts to junior faculty and other early-career scientists involved with the PAM IRC. Dr. Salama studies Helicobacter pylori, a common bacterial pathogen linked to stomach ulcers, a majority of gastric cancer cases and certain lymphomas.
Dr. Hootie Warren, MD, PhD
As head of the Fred Hutch Global Oncology Program, Dr. Hootie Warren links PAM IRC research interests with ongoing work in areas of the world most impacted by pathogen-associated malignancies. He balances clinical care of patients with blood cancers with cancer immunology research. A major focus of his research is Burkitt lymphoma, a common B-cell cancer in sub-Saharan Africa that is caused by the Epstein–Barr virus.
Dr. Paul Nghiem, MD, PhD
Dr. Paul Nghiem brings clinical and translational expertise to the PAM IRC. He is a world expert in the study and treatment of Merkel cell carcinoma, an aggressive, rare skin cancer that is linked to Merkel cell polyomavirus in 80 percent of cases.
PAM IRC Faculty
Select a letter to display a list of Faculty members
The mechanisms by which viruses hijack chromatin. Due to the major advancement in sequencing technologies and the expansion of the field of epigenetics, exploiting viruses to investigate chromatin biology has enormous potential.
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infection complications, genome and gene expression studies.
Research is centered on 1) understanding the factors associated with successful adoptive transfer of immune T cells and improving the outcomes of both native and gene-modified T cells targeting viral and tumor antigens, 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T-cell products so as to better eliminate tumor targets and 3) clinical strategies to modulate the host immune environment as a means to optimally activate T cells in humans.
Determining how changes in microbial communities impact human health; identifying, characterizing, and culturing microbes found in the human genital tract; and associating the reproductive tract microbiome with human disease.
Developing molecular diagnostic tests to detect and identify pathogens in immunocompromised hosts such as cancer patients.
The Galloway Lab studies the mechanisms by which human papillomaviruses contribute to cancer, with an emphasis on types most likely to progress to cervical cancer. They work to understand the natural history of genital HPV infections and why only a small subset of women infected with high-risk HPVs develop cancer.
Developing methods and tools for high-throughput, high-dimensional experiments with applications in vaccine research, immunology and immunotherapy; flow cytometry, peptide microarrays, next generation sequencing; Bayesian inference and computation and statistical computing
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
Research focuses on development and application of novel methods for identifying and characterizing antigen specific T cells in the context of cancer and chronic infection with the goal of identifying specific and accurate biomarkers of human health and disease based on antigen-specific T cells.
New ways to prevent and treat skin cancers
by studying the systems that control cell division. These systems help prevent cells with damaged DNA from reproducing and, when they malfunction, can affect cells’ chances of becoming cancerous.
The Overbaugh lab has a long-standing interest in understanding the mechanisms of HIV-1 transmission and pathogenesis. The lab is part of a larger team, comprising researchers in both Seattle and Kenya (The Nairobi HIV/STD Project). Trainees in the lab have opportunities to engage in studies of viral evolution, virus-host cell interactions, and viral immunology all within the context of international collaboration.
Studies focus on 1) understanding the roles of distinct T cell subsets in protective immunity to pathogens and tumors and on 2) the development and clinical application of adoptive T cell therapies for viral diseases and cancers, using unmodified and genetically modified antigen-specific T cells.
Interest in describing the quantitative and dynamical features of human pathogens and immune responses. Most of work to-date is on the pathogenesis of HSV-2 infection but also interested in applying models to optimize viral eradication strategies, and to use models to capture kinetic features of the human microbiome.
Research is focused on the development of a safe and effective vaccine to combat the spread of HIV and to investigate how HIV infection leads to AIDS. Two major areas of research is to better understand how neutralizing antibodies against HIV are developed during natural HIV-infection,and engineer immunogens that will elicit broadly neutralizing antibody responses against HIV.
Research interests involve mechanisms driving the differentiation of B cells following vaccination and infection, understanding how differences in the pre-immune repertoire influences immunity and vaccine Development
Clinical focus is treating patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. Research is focused on cancer immunology, specifically the mechanisms and molecules that mediate graft-versus-host disease and graft-versus tumor.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.